Adriana Davis, DO
Family Medicine · Burlington, NJNPI 1225373111
Payments from drug & device makers
Across 351 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$522
- Boehringer Ingelheim$355
- Lilly USA, LLC$315
- Sanofi-aventis U.S. LLC$303
- AbbVie$298
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,381100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 105 | $1,330 |
| AstraZeneca | 30 | $522 |
| Boehringer Ingelheim | 23 | $355 |
| Lilly USA, LLC | 23 | $315 |
| Sanofi-aventis U.S. LLC | 20 | $303 |
| AbbVie(2 entities) | 19 | $298 |
| Merck | 19 | $264 |
| Exact Sciences | 9 | $202 |
| Astellas Pharma US Inc | 10 | $192 |
| Abbott | 10 | $176 |
| Pfizer | 11 | $174 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $133 |
| Inspire Medical Systems, Inc. | 3 | $123 |
| Amgen | 8 | $120 |
| Novartis | 8 | $119 |
| GSK | 7 | $113 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
| Dexcom, Inc. | 3 | $59 |
| Bayer | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Si-bone, Inc. | 2 | $40 |
| Almatica Pharma LLC | 2 | $34 |
| Eisai Inc. | 2 | $32 |
| Insulet Corporation | 1 | $27 |
| Johnson & Johnson | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Bausch Health US, LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Medtronic | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$5,381 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 87 | $92,197 |
| OzempicSemaglutide | 49 | $68,166 |
| JanuviaSitagliptin Phosphate | 45 | $53,473 |
| JardianceEmpagliflozin | 57 | $49,299 |
| MounjaroTirzepatide | 24 | $26,742 |
| EntrestoSacubitril/Valsartan | 14 | $26,251 |
| FarxigaDapagliflozin Propanediol | 15 | $19,836 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $16,977 |
| LinzessLinaclotide | 14 | $13,264 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $8,221 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $6,879 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $6,853 |
| Atorvastatin Calcium | 555 | $6,810 |
| VascepaIcosapent Ethyl | 24 | $4,350 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 137 | $3,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $174 | $92,19787 claims |
| MerckJanuvia, Janumet, Janumet Xr | $264 | $77,30368 claims |
| Novo NordiskOzempic | $1,330 | $68,16649 claims |
| Boehringer IngelheimJardiance | $355 | $49,29957 claims |
| Lilly USA, LLCMounjaro | $315 | $26,74224 claims |
| NovartisEntresto | $119 | $26,25114 claims |
| AstraZenecaFarxiga | $522 | $19,83615 claims |
| AbbVieLinzess | $298 | $13,26414 claims |
| GSKBreo Ellipta | $113 | $8,22112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Burlington
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.